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Abstract
CRISPR-Cas systems provide microbes with adaptive immunity to infectious 
nucleic acids and are widely employed as genome editing tools. These tools 
use RNA-guided Cas proteins whose large size (950 to 1400 amino acids) has
been considered essential to their specific DNA- or RNA-targeting activities. 
Here we present a set of CRISPR-Cas systems from uncultivated archaea that
contain Cas14, a family of exceptionally compact RNA-guided nucleases (400
to 700 amino acids). Despite their small size, Cas14 proteins are capable of 
targeted single-stranded DNA (ssDNA) cleavage without restrictive sequence
requirements. Moreover, target recognition by Cas14 triggers nonspecific 
cutting of ssDNA molecules, an activity that enables high-fidelity single-
nucleotide polymorphism genotyping (Cas14-DETECTR). Metagenomic data 
show that multiple CRISPR-Cas14 systems evolved independently and 
suggest a potential evolutionary origin of single-effector CRISPR-based 
adaptive immunity.
Introduction
Competition between microbes and viruses stimulated the evolution of 
CRISPR-based adaptive immunity to provide protection against infectious 
agents (1, 2). In class 2 CRISPR-Cas systems, a single 100- to 200-kDa 
CRISPR-associated (Cas) protein with multiple functional domains carries out 
RNA-guided binding and cutting of DNA or RNA substrates (3, 4). To 
determine whether simpler, smaller RNA-guided proteins occur in nature, we 
queried terabase-scale metagenomic datasets (5–9) for uncharacterized 
genes proximal to both a CRISPR array and cas1, the gene that encodes the 
universal CRISPR integrase (10, 11). This analysis identified a diverse family 
of CRISPR-Cas systems that contain cas1, cas2, cas4, and a previously 
unrecognized gene, cas14, encoding a 40- to 70-kDa polypeptide (Fig. 1A). 
We initially identified 24 different cas14 gene variants that cluster into three 
subgroups (Cas14a, Cas14b, and Cas 14c) on the basis of comparative 
sequence analysis (Fig. 1, A and B, and figs. S1 and S2). Cas14 proteins are 
~400 to 700 amino acids (aa), about half the size of previously known class 
2 CRISPR RNA-guided enzymes (950 to 1400 aa) (Fig. 1, C and D). Though 
the identified Cas14 proteins exhibit considerable sequence diversity, all are 
united by the presence of a predicted RuvC nuclease domain, whose 
organization is characteristic of type V CRISPR-Cas DNA-targeting enzymes 
(Fig. 1D) (3, 12, 13).
The Cas14 proteins we identified occur almost exclusively within DPANN, a 
superphylum of symbiotic archaea characterized by small cell and genome 
sizes (14, 15). Phylogenetic comparisons showed that Cas14 proteins are 
widely diverse with similarities to C2c10 and C2c9, families of bacterial RuvC
domain–containing proteins that are sometimes found near a CRISPR array 
but not together with other cas genes (Fig. 1B and fig. S1) (3). This 
observation and the small size of the c2c10, c2c9, and cas14 genes made it 
improbable that these systems could function as stand-alone CRISPR 
effectors (3).
On the basis of their proximity to conserved genes responsible for creating 
genetic memory of infection (cas1, cas2, cas4) (fig. S3A), we explored 
whether CRISPR-Cas14 systems can actively acquire DNA sequences into 
their CRISPR arrays. Assembled metagenomic contiguous DNA sequences 
(contigs) for multiple CRISPR-Cas14 loci revealed that otherwise identical 
CRISPR systems showed diversity in their CRISPR arrays. These results are 
consistent with active adaptation to new infections, although without 
longitudinal sampling these data could also be explained by alternative 
biological mechanisms (Fig. 2A and fig. S3B) (13). The evidence suggesting 
acquisition of new DNA sequences led us to hypothesize that these CRISPR-
Cas14 loci encode functional enzymes with nucleic acid targeting activity 
despite their small size. To test this possibility, we first investigated whether 
RNA components are produced from CRISPR-Cas14 loci. Environmental 
metatranscriptomic sequencing data were analyzed for the presence of RNA 
from the native archaeal host that contains CRISPR-Cas14a (Fig. 2B and fig. 
S4A). In addition to CRISPR RNAs (crRNAs), a highly abundant noncoding RNA
was mapped to a ~130–base pair sequence located between cas14a and the 
adjacent CRISPR array. Notably, the 3′ end of this transcript was mostly 
complementary to the repeat segment of the crRNA (Fig. 2C and fig. S4B), as
observed for trans-activating CRISPR RNAs (tracrRNAs) found in association 
with Cas9, Cas12b, and Cas12e CRISPR systems (12, 13, 16). In these 
previously studied systems, the double-stranded RNA–cutting enzyme 
ribonuclease III (RNase III) generates mature tracrRNAs and crRNAs, but no 
genes encoding RNase III were present in cas14-containing reconstructed 
genomes (fig. S5A), nor did Cas14a cleave its own pre-crRNA when tested 
biochemically (fig. S5B). These observations imply that an alternative 
mechanism for CRISPR-associated RNA processing exists in these hosts.
To test whether the Cas14a proteins and associated RNA components can 
assemble together in a heterologous organism, we introduced a plasmid 
into Escherichia coli containing a minimal CRISPR-Cas14a locus that includes 
the cas14 gene, the CRISPR array, and intergenic regions containing the 
putative tracrRNA. Affinity purification of the Cas14a protein from cell lysate 
and sequencing of copurifying RNA revealed a highly abundant mature 
crRNA as well as the putative tracrRNA, albeit in lower relative abundance 
than what was shown by environmental metatranscriptomics, suggesting 
that Cas14 associates with both crRNA and tracrRNA (fig. S5C). The 
calculated mass of the assembled Cas14a protein–tracrRNA–crRNA particle is
48% RNA by weight compared with just 17% for Streptococcus 
pyogenes Cas9 (SpCas9) and 8% for Francisella novicida Cas12a (FnCas12a) 
(Fig. 2D), hinting at a central role of the RNA in the architecture of the 
Cas14a complex. Known class 2 CRISPR systems require a short sequence 
called a protospacer adjacent motif (PAM) to target double-stranded DNA 
(dsDNA) (17). To test whether Cas14a requires a PAM and can conduct 
dsDNA interference, we transformed E. coli expressing a minimal Cas14a 
locus with a dsDNA plasmid containing a randomized PAM region next to a 
sequence matching the target-encoding sequence (spacer) in the Cas14 
array. Notably, no depletion of a PAM sequence was detected among E. 
coli transformants, suggesting that the CRISPR-Cas14a system is unable to 
target dsDNA, can do so without requiring a PAM, or is inactive in this 
heterologous host (fig. S6, A and B).
We next tested whether purified Cas14a-tracrRNA-crRNA complexes are 
capable of RNA-guided nucleic acid cleavage in vitro. All currently 
reconstituted DNA-targeting class 2 interference complexes are able to 
recognize both dsDNA and single-stranded DNA (ssDNA) substrates (18–20). 
We incubated purified Cas14a-tracrRNA-crRNA complexes with radiolabeled 
target oligonucleotides (ssDNA, dsDNA, and ssRNA) bearing a 20-nucleotide 
sequence complementary to the crRNA guide sequence or a 
noncomplementary ssDNA, and we analyzed these substrates for Cas14a-
mediated cleavage. Only in the presence of a complementary ssDNA 
substrate was any cleavage product detected (Fig. 3A and fig. S7, A to C), 
and cleavage was dependent on the presence of both tracrRNA and crRNA, 
which could also be combined into a single-guide RNA (sgRNA) (Fig. 3B and 
fig. S8). The lack of detectable dsDNA cleavage suggests that Cas14a targets
ssDNA selectively, although it is possible that some other host factor or 
sequence requirement could enable dsDNA recognition in the native host. 
Mutation of the conserved active site residues in the Cas14a RuvC domain 
eliminated cleavage activity (fig. S7, D and E), implicating RuvC as the 
domain responsible for DNA cutting. Moreover, Cas14a DNA cleavage was 
sensitive to truncation of the RNA components to lengths shorter than the 
naturally produced sequences (fig. S9, A to D). These results establish 
Cas14a as the smallest class 2 CRISPR effector demonstrated to conduct 
programmable RNA-guided DNA cleavage thus far.
Although we were unable to identify a dsDNA PAM in vivo, we tested whether
Cas14a requires a PAM for ssDNA cleavage in vitro by tiling Cas14a guides 
across a ssDNA substrate (Fig. 3C). Despite sequence variation adjacent to 
the targets of these different guides, we observed cleavage for all four 
sequences. Notably, the cleavage sites occur beyond the guide-
complementary region of the ssDNA and shift in response to guide binding 
position (Fig. 3C). These data demonstrate Cas14a is a ssDNA-targeting 
CRISPR endonuclease that does not require a PAM for activation.
On the basis of the observation that Cas14a cuts outside of the crRNA/DNA 
targeting heteroduplex, we hypothesized that Cas14a might possess target-
activated nonspecific ssDNA cleavage activity, similar to the RuvC-containing
enzyme Cas12a (20, 21). To test this possibility, we incubated Cas14a-
tracrRNA-crRNA with a complementary activator DNA and an aliquot of M13 
bacteriophage ssDNA bearing no sequence complementarity to the Cas14a 
crRNA or activator (Fig. 3D). The M13 ssDNA was rapidly degraded to small 
fragments, an activity that was eliminated by mutation of the conserved 
Cas14a RuvC active site, suggesting that activation of Cas14a results in 
nonspecific ssDNA degradation. However, we were unable to observe 
Cas14a-mediated interference against the ssDNA bacteriophage ΦX174 X174 
when we expressed Cas14a heterologously in E. coli (fig. S10, A to C), 
possibly due to the dissimilarity between E. coli and Cas14a’s native 
archaeal host. To investigate the specificity of target-dependent nonspecific 
DNA cutting activity by Cas14a, we adapted a fluorophore-quencher (FQ) 
assay in which cleavage of dye-labeled ssDNA generates a fluorescent signal
(Fig. 4A) (22). When Cas14a was incubated with various guide RNA–target 
ssDNA pairs, a fluorescent signal was observed only in the presence of the 
cognate target and showed strong preference for longer FQ-containing 
substrates (fig. S10D and Fig. 4A). We next tested Cas14a mismatch 
tolerance by tiling 2-nucleotide mismatches across the targeted region in 
various ssDNA substrates. Surprisingly, mismatches near the middle of the 
ssDNA target strongly inhibited Cas14a activity, revealing an internal seed 
sequence that is distinct from the PAM-proximal seed region observed for 
dsDNA-targeting CRISPR-Cas systems (Fig. 4B and fig. S11, A to D). 
Moreover, DNA substrates containing strong secondary structure resulted in 
reduced activation of Cas14a (fig. S11E). Truncation of ssDNA substrates also
resulted in reduced or undetectable trans cleavage (fig. S11F). Together, 
these results suggest a mechanism of fidelity distinct from dsDNA-targeting 
class 2 CRISPR systems, possibly using a mechanism similar to the ssRNA-
targeting Cas13a enzymes (23–25).
The target-dependent, nonspecific DNase activity of Cas12a serves as a DNA
detection platform (DNA endonuclease-targeted CRISPR trans reporter, or 
DETECTR) for diagnostic uses (20, 26). Although Cas12a exhibits low fidelity 
in discriminating against ssDNA substrates (20), Cas14a requires 
complementarity in the seed region for ssDNA substrate recognition. This 
improved specificity raised the possibility of using Cas14a for high-fidelity 
detection of DNA single-nucleotide polymorphisms (SNPs) without the 
constraint of a PAM sequence. To test this idea, DNA substrates were 
amplified using a phosphorothioate (PT)–containing primer to protect one 
strand from degradation by exonucleases. Upon addition of T7 exonuclease, 
the unmodified strand was degraded, leaving ssDNA substrates that can be 
detected by Cas14a (Fig. 4, C and D). As a proof of principle, we aimed to 
detect the human HERC2 gene, which contains a SNP responsible for eye 
color (27). We amplified the HERC2 gene from DNA in human saliva from 
both blue-eyed and brown-eyed individuals, using the PT amplification 
approach described above. When programmed with a guide RNA targeting 
the blue-eyed SNP, Cas12a failed to discriminate between the two ssDNA 
targets, exhibiting robust trans activity in both cases, whereas Cas14a 
exhibited strong activation in recognition of the blue-eyed SNP with near-
background signal for the brown-eyed sample (Fig. 4E). The development of 
Cas14-DETECTR now allows for CRISPR-based detection of medically and 
ecologically important ssDNA pathogens as well as high-fidelity detection of 
SNPs without the constraint of a PAM sequence.
Further investigation of compact type V systems in metagenomic data 
revealed a large diversity of systems that, like Cas14a to Cas14c, include a 
gene encoding a short RuvC-containing protein adjacent to acquisition-
associated cas genes and a CRISPR array. We found 20 additional such 
systems in various uncultivated microbes that cluster into five main families 
(Cas14d to Cas14h). Excluding cas14g, which is related to cas12b, the cas14-
like genes form separate clades on the type V effector phylogeny (fig. S12, A 
and B), suggesting that these families evolved from independent 
domestication events of TnpB, the transposase-associated protein implicated
as the evolutionary ancestor of type V CRISPR effectors (3). Phylogenetic 
reconstruction of their associated cas1 genes indicated that they too have 
different origins for the cas14 subtypes (fig. S2). Altogether, we identified 38 
CRISPR-Cas14 systems belonging to eight families (Cas14a to Cas14h) and 
eight additional systems that could not be clustered with our analysis 
(termed Cas14u) (data S3).
The small size of the Cas14 proteins described here and their resemblance to
type V effector proteins suggest that RNA-guided ssDNA cleavage may have 
existed as an ancestral class 2 CRISPR system (28, 29). In this scenario, a 
small, domesticated TnpB-like ssDNA interference complex may have gained
additional domains over time, gradually improving dsDNA recognition and 
cleavage. Related to this hypothesis, smaller Cas9 orthologs exhibit weaker 
dsDNA-targeting activity than their larger counterparts but retain the ability 
to robustly cleave ssDNA (19). Aside from the evolutionary implications, the 
ability of Cas14 to specifically target ssDNA suggests a role in defense 
against ssDNA viruses or mobile genetic elements that propagate through 
ssDNA intermediates (30). A ssDNA-targeting CRISPR system would be 
particularly advantageous in certain ecosystems where ssDNA viruses 
constitute the vast majority of viral abundance (31). The unexpected finding 
that these miniature CRISPR proteins can conduct targeted DNA cleavage 
highlights the diversity of CRISPR systems hidden in uncultivated organisms. 
Ongoing exploration of these underrepresented microbial lineages will likely 
continue to reveal new, unexpected insights into this microscopic arms race 
and lead to continued development of valuable CRISPR-based technologies.
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